Patient characteristics
| . | Ruxolitinib (n = 62) . | Nonruxolitinib therapies (n = 105) . | P value . |
|---|---|---|---|
| Median age at transplant (range) | 57 (18-73) | 58 (18-72) | .92 |
| Sex, n (%) | .42 | ||
| Female | 30 (48) | 43 (41) | |
| Male | 32 (52) | 62 (59) | |
| Indication for HCT, n (%) | .42 | ||
| Acute leukemia | 35 (56) | 47 (45) | |
| MDS/MPN | 15 (24) | 45 (43) | |
| Lymphoma | 8 (13) | 9 (9) | |
| Other | 4 (6) | 4 (4) | |
| Donor type, n (%) | .014 | ||
| Related | 9 (15) | 31 (30) | |
| Unrelated | 46 (74) | 71 (67) | |
| Haploidentical | 7 (11) | 3 (3) | |
| HLA match, n (%) | .08 | ||
| Matched | 47 (76) | 89 (85) | |
| Mismatched | 8 (13) | 13 (12) | |
| Haploidentical | 7 (11) | 3 (3) | |
| Stem cell source, n (%) | .55 | ||
| Peripheral blood | 51 (82) | 79 (75) | |
| BM | 9 (15) | 20 (19) | |
| Cord blood | 2 (3) | 6 (6) | |
| Conditioning regimen intensity, n (%) | .26 | ||
| Myeloablative | 35 (56) | 49 (47) | |
| Reduced intensity | 27 (44) | 56 (53) | |
| GVHD prophylaxis, n (%) | .08 | ||
| CNI-based | 48 (77%) | 94 (90%) | |
| PTCy-based | 12 (19%) | 7 (7%) | |
| Other | 2 (3%) | 4 (3%) | |
| Median days from steroids to second line therapy (range) | 18 (1-45) | 12 (2-80) | .02 |
| Reason for second line treatment, n (%) | .65 | ||
| Steroid resistance | 53 (84) | 93 (89) | |
| Steroid dependence | 4 (6) | 4 (4) | |
| Steroid sparing | 5 (8) | 8 (7) | |
| Organ involvement at second line therapy, n (%) | |||
| Skin | 32 (52) | 48 (46) | .52 |
| Liver | 4 (10) | 16 (15) | .35 |
| Upper GI | 11 (18) | 24 (23) | .56 |
| Lower GI | 38 (61) | 70 (67) | .51 |
| GVHD grade at second line therapy, n (%) | .14 | ||
| 0 | 4 (7) | 1 (1) | |
| 1 | 7 (11) | 12 (11) | |
| 2 | 13 (21) | 30 (29) | |
| 3 | 19 (31) | 40 (38) | |
| 4 | 19 (31) | 22 (21) | |
| Total bilirubin concentration (mg/dL) at second line therapy, n (%) | .31 | ||
| <2 | 55 (89) | 88 (84) | |
| 2 to 3.9 | 2 (3) | 10 (10) | |
| ≥4 | 5 (8) | 7 (7) | |
| MAP at second line therapy, n (%) | .53 | ||
| High | 28 (45) | 53 (51) | |
| Low | 34 (55) | 52 (49) | |
| Year of systemic GVHD therapy | <.001 | ||
| 2016 to 2018 | 23 (37) | 74 (70) | |
| 2019 to 2021 | 39 (63) | 31 (30) |
| . | Ruxolitinib (n = 62) . | Nonruxolitinib therapies (n = 105) . | P value . |
|---|---|---|---|
| Median age at transplant (range) | 57 (18-73) | 58 (18-72) | .92 |
| Sex, n (%) | .42 | ||
| Female | 30 (48) | 43 (41) | |
| Male | 32 (52) | 62 (59) | |
| Indication for HCT, n (%) | .42 | ||
| Acute leukemia | 35 (56) | 47 (45) | |
| MDS/MPN | 15 (24) | 45 (43) | |
| Lymphoma | 8 (13) | 9 (9) | |
| Other | 4 (6) | 4 (4) | |
| Donor type, n (%) | .014 | ||
| Related | 9 (15) | 31 (30) | |
| Unrelated | 46 (74) | 71 (67) | |
| Haploidentical | 7 (11) | 3 (3) | |
| HLA match, n (%) | .08 | ||
| Matched | 47 (76) | 89 (85) | |
| Mismatched | 8 (13) | 13 (12) | |
| Haploidentical | 7 (11) | 3 (3) | |
| Stem cell source, n (%) | .55 | ||
| Peripheral blood | 51 (82) | 79 (75) | |
| BM | 9 (15) | 20 (19) | |
| Cord blood | 2 (3) | 6 (6) | |
| Conditioning regimen intensity, n (%) | .26 | ||
| Myeloablative | 35 (56) | 49 (47) | |
| Reduced intensity | 27 (44) | 56 (53) | |
| GVHD prophylaxis, n (%) | .08 | ||
| CNI-based | 48 (77%) | 94 (90%) | |
| PTCy-based | 12 (19%) | 7 (7%) | |
| Other | 2 (3%) | 4 (3%) | |
| Median days from steroids to second line therapy (range) | 18 (1-45) | 12 (2-80) | .02 |
| Reason for second line treatment, n (%) | .65 | ||
| Steroid resistance | 53 (84) | 93 (89) | |
| Steroid dependence | 4 (6) | 4 (4) | |
| Steroid sparing | 5 (8) | 8 (7) | |
| Organ involvement at second line therapy, n (%) | |||
| Skin | 32 (52) | 48 (46) | .52 |
| Liver | 4 (10) | 16 (15) | .35 |
| Upper GI | 11 (18) | 24 (23) | .56 |
| Lower GI | 38 (61) | 70 (67) | .51 |
| GVHD grade at second line therapy, n (%) | .14 | ||
| 0 | 4 (7) | 1 (1) | |
| 1 | 7 (11) | 12 (11) | |
| 2 | 13 (21) | 30 (29) | |
| 3 | 19 (31) | 40 (38) | |
| 4 | 19 (31) | 22 (21) | |
| Total bilirubin concentration (mg/dL) at second line therapy, n (%) | .31 | ||
| <2 | 55 (89) | 88 (84) | |
| 2 to 3.9 | 2 (3) | 10 (10) | |
| ≥4 | 5 (8) | 7 (7) | |
| MAP at second line therapy, n (%) | .53 | ||
| High | 28 (45) | 53 (51) | |
| Low | 34 (55) | 52 (49) | |
| Year of systemic GVHD therapy | <.001 | ||
| 2016 to 2018 | 23 (37) | 74 (70) | |
| 2019 to 2021 | 39 (63) | 31 (30) |
Bold values indicate statistical significance P < 0.05.
CNI, calcineurin inhibitor; HLA, human leukocyte antigen; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; PTCy, posttransplant cyclophosphamide.